eNOS-话题@MedSci

#eNOS#

17篇内容 | 1107人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1985364, encodeId=945e19853640d, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=肝癌药物Namodenoson在罗马尼亚获批作为同情用药治疗晚期肝癌, objectType=article, longId=736907, objectId=02cce36907c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02cce36907c7, replyNumber=0, likeNumber=98, createdTime=2023-04-30, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02cce36907c7, moduleTitle=肝癌药物Namodenoson在罗马尼亚获批作为同情用药治疗晚期肝癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02cce36907c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985363, encodeId=835d1985363e5, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, objectType=article, longId=728244, objectId=9c3ce282447f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3ce282447f, replyNumber=0, likeNumber=86, createdTime=2022-12-17, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3ce282447f, moduleTitle=ASCO：Denosumab辅助治疗乳腺癌的长期预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3ce282447f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985362, encodeId=6596198536273, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=N6-methyladenosine could indirectly modulate translation in human cancer cells via cis-elements, objectType=article, longId=220905, objectId=6600220905d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6600220905d0, replyNumber=0, likeNumber=0, createdTime=2022-08-30, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6600220905d0, moduleTitle=N6-methyladenosine could indirectly modulate translation in human cancer cells via cis-elements, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6600220905d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985361, encodeId=e69c1985361e9, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, objectType=article, longId=203277, objectId=fdc22032e7e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdc22032e7e0, replyNumber=0, likeNumber=61, createdTime=2021-02-21, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdc22032e7e0, moduleTitle=韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdc22032e7e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985360, encodeId=539f198536038, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, objectType=article, longId=196884, objectId=c1dc196884ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1dc196884ba, replyNumber=0, likeNumber=92, createdTime=2021-06-05, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1dc196884ba, moduleTitle=非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1dc196884ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985359, encodeId=02a31985359d0, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, objectType=article, longId=191736, objectId=e771191e364a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e771191e364a, replyNumber=0, likeNumber=94, createdTime=2020-11-30, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e771191e364a, moduleTitle=A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e771191e364a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985358, encodeId=6c3c1985358ec, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响, objectType=article, longId=184114, objectId=ffed184114fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffed184114fe, replyNumber=0, likeNumber=68, createdTime=2020-07-18, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffed184114fe, moduleTitle=Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffed184114fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985357, encodeId=4fee198535e28, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=Lancet Oncol：Denosumab治疗骨巨细胞瘤, objectType=article, longId=182590, objectId=db251825901e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db251825901e, replyNumber=0, likeNumber=79, createdTime=2020-02-19, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db251825901e, moduleTitle=Lancet Oncol：Denosumab治疗骨巨细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db251825901e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985356, encodeId=bf92198535635, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性, objectType=article, longId=160285, objectId=69931602858e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69931602858e, replyNumber=0, likeNumber=66, createdTime=2019-03-26, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69931602858e, moduleTitle=J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69931602858e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985355, encodeId=3e85198535586, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响, objectType=article, longId=158923, objectId=ebd9158923fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebd9158923fd, replyNumber=0, likeNumber=76, createdTime=2019-12-31, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebd9158923fd, moduleTitle=Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebd9158923fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985352, encodeId=9b7d1985352aa, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率, objectType=article, longId=136478, objectId=bc951364e8ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc951364e8ab, replyNumber=0, likeNumber=84, createdTime=2019-02-17, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc951364e8ab, moduleTitle=WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc951364e8ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985354, encodeId=38be198535433, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症, objectType=article, longId=138882, objectId=329f13888260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=329f13888260, replyNumber=0, likeNumber=81, createdTime=2018-12-15, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=329f13888260, moduleTitle=FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=329f13888260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985351, encodeId=22ed198535177, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生, objectType=article, longId=135575, objectId=08e81355e529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08e81355e529, replyNumber=0, likeNumber=68, createdTime=2018-12-18, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08e81355e529, moduleTitle=Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08e81355e529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985353, encodeId=cf5d198535339, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, objectType=article, longId=136728, objectId=2a86136e2899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a86136e2899, replyNumber=0, likeNumber=80, createdTime=2019-02-03, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a86136e2899, moduleTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a86136e2899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985350, encodeId=c4f71985350eb, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=EUR J Cancer：denosumab时代下的骨巨细胞瘤, objectType=article, longId=125003, objectId=e0271250030e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0271250030e, replyNumber=0, likeNumber=86, createdTime=2018-09-07, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0271250030e, moduleTitle=EUR J Cancer：denosumab时代下的骨巨细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0271250030e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985349, encodeId=95ea198534934, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？, objectType=article, longId=124995, objectId=c98d12499593, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c98d12499593, replyNumber=0, likeNumber=69, createdTime=2018-12-13, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c98d12499593, moduleTitle=EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c98d12499593)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985348, encodeId=aa7c19853487e, content=<a href='/topic/show?id=3c2c6803a2' target=_blank style='color:#2F92EE;'>#eNOS#</a>, objectTitle=PNAS：血管内皮细胞“Gab1-PKA-eNOS”信号转导通路在缺血性血管新生过程中起关键作用, objectType=article, longId=2364, objectId=556c2364f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556c2364f3, replyNumber=0, likeNumber=100, createdTime=2011-08-05, rootId=0, userName=12498bb3m90(暂无昵称), userId=7a5c2500147, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556c2364f3, moduleTitle=PNAS：血管内皮细胞“Gab1-PKA-eNOS”信号转导通路在缺血性血管新生过程中起关键作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556c2364f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

eNOS

2020-05-29

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

肝癌药物Namodenoson在罗马尼亚获批作为同情用药治疗晚期肝癌

2023-04-30

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

ASCO：Denosumab辅助治疗乳腺癌的长期预后

2022-12-17

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

N6-methyladenosine could indirectly modulate translation in human cancer cells via cis-elements

2022-08-30

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

韩国三星的生物仿制药阵营或再添新成员：开始针对Denosumab生物类似物SB16进行I期临床试验

2021-02-21

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

非酒精性脂肪性肝炎（NASH）新药Namodenoson：所有功效指标均得到显着且持续改善

2021-06-05

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

A3腺苷受体激动剂Namodenoson，治疗非酒精性脂肪性肝炎（NASH）的II期研究成功

2020-11-30

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

Lancet Oncol：Denosumab对早期乳腺癌患者骨转移的影响

2020-07-18

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

Lancet Oncol：Denosumab治疗骨巨细胞瘤

2020-02-19

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

J Clin Med：Denosumab治疗骨质疏松症骨质疏松症的疗效和安全性

2019-03-26

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

Hematology：Denosumab对输血依赖性地中海贫血和骨质疏松症患者血清骨形态发生蛋白拮抗剂noggin的影响

2019-12-31

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

WCO会议：Denosumab的长期使用能够降低绝经后骨质疏松症患者的骨折发生率

2019-02-17

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

FDA批准Denosumab用于糖皮质激素诱导的骨质疏松症

2018-12-15

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

Front Pharmacol：Kinsenoside通过Erk / p38 / NF-κB/ VEGF信号改善氧化应激诱导的RPE细胞凋亡并抑制血管发生

2018-12-18

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者

2019-02-03

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

EUR J Cancer：denosumab时代下的骨巨细胞瘤

2018-09-07

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

EUR J Cancer：Denosumab用于晚期/不可切除的骨巨细胞瘤（GCTB）：未来的路要走多久？

2018-12-13

12498bb3m90(暂无昵称) (审核中...)

前往app查看评论内容

#eNOS#

PNAS：血管内皮细胞“Gab1-PKA-eNOS”信号转导通路在缺血性血管新生过程中起关键作用

2011-08-05

科室
- - 订阅+
  - 更多科室
工具
服务